• Philippe Moreau, Meletios A Dimopoulos, Kwee Yong, Joseph Mikhael, Marie-Laure Risse, Gaëlle Asset, and Thomas Martin.
• Department of Hematology, University Hospital, Allée de l'Ile Gloriette, Nantes, 44093, France.
• Future Oncol. 2020 Jan 1; 16 (2): 4347-4358.

AbstractAlthough the treatment of relapsed/refractory multiple myeloma has improved dramatically over the past decade, the disease remains incurable; therefore, additional therapies are needed. Novel combination therapies incorporating monoclonal antibodies have shown significant promise. Here we describe the design of a Phase III study (NCT03275285, IKEMA), which is evaluating isatuximab plus carfilzomib and low-dose dexamethasone, versus carfilzomib/dexamethasone in relapsed/refractory multiple myeloma. The primary end point is progression-free survival. Responses are being determined by an independent review committee using 2016 International Myeloma Working Group criteria, and safety will be assessed throughout. The first patient was recruited in November 2017, and the last patient was recruited in March 2019; 302 patients have been randomized, and the study is ongoing. Clinical trial registration: NCT03275285.

40 keywords...

hide…